Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Verploegen

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
European Journal of Biochemistry|September 17, 2002
Role of Ca2+/calmodulin regulated signaling pathways in chemoattractant induced neutrophil effector functions. Comparison with the role of phosphotidylinositol-3 kinaseSandra Verploegen, Caroline M van Leeuwen, Hanneke W M van Deutekom, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2012
Crosstalk between human IgG isotypes and murine effector cellsMarije B Overdijk, Sandra Verploegen, Antonio Ortiz Buijsse, et al.
Blood|September 25, 2007
Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesisMiranda Buitenhuis, Liesbeth P Verhagen, Hanneke W M van Deutekom, et al.
Blood|April 21, 2005
Characterization of the role of CaMKI-like kinase (CKLiK) in human granulocyte functionSandra Verploegen, Laurien Ulfman, Hanneke W M van Deutekom, et al.
Molecular Cancer Therapeutics|November 2, 2018
CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective MemoryHreinn Benonisson, Işıl Altıntaş, Marjolein Sluijter, et al.
Scientific Reports|June 1, 2017
Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent ModelsAran F Labrijn, Joyce I Meesters, Matthew Bunce, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 12, 2011
Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibitionMarije B Overdijk, Sandra Verploegen, Jeroen H van den Brakel, et al.
Journal of Oncology|January 17, 2022
Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer CellsMandy Gruijs, Rens Braster, Marije B Overdijk, et al.
Cancer Research|December 28, 2013
An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumorsEsther C W Breij, Bart E C G de Goeij, Sandra Verploegen, et al.
Mabs|March 12, 2015
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomaMarije B Overdijk, Sandra Verploegen, Marijn Bögels, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
European Journal of Biochemistry|September 17, 2002
Role of Ca2+/calmodulin regulated signaling pathways in chemoattractant induced neutrophil effector functions. Comparison with the role of phosphotidylinositol-3 kinaseSandra Verploegen, Caroline M van Leeuwen, Hanneke W M van Deutekom, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2012
Crosstalk between human IgG isotypes and murine effector cellsMarije B Overdijk, Sandra Verploegen, Antonio Ortiz Buijsse, et al.
Blood|September 25, 2007
Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesisMiranda Buitenhuis, Liesbeth P Verhagen, Hanneke W M van Deutekom, et al.
Blood|April 21, 2005
Characterization of the role of CaMKI-like kinase (CKLiK) in human granulocyte functionSandra Verploegen, Laurien Ulfman, Hanneke W M van Deutekom, et al.
Molecular Cancer Therapeutics|November 2, 2018
CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective MemoryHreinn Benonisson, Işıl Altıntaş, Marjolein Sluijter, et al.
Scientific Reports|June 1, 2017
Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent ModelsAran F Labrijn, Joyce I Meesters, Matthew Bunce, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 12, 2011
Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibitionMarije B Overdijk, Sandra Verploegen, Jeroen H van den Brakel, et al.
Journal of Oncology|January 17, 2022
Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer CellsMandy Gruijs, Rens Braster, Marije B Overdijk, et al.
Cancer Research|December 28, 2013
An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumorsEsther C W Breij, Bart E C G de Goeij, Sandra Verploegen, et al.
Mabs|March 12, 2015
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomaMarije B Overdijk, Sandra Verploegen, Marijn Bögels, et al.
Pageof 2